ADPT
NASDAQAdaptive Biotechnologies Corporation
Price$22.92+8.39 (+57.69%)
2026-04-142026-07-17
News · 26 weeks80-27%
2026-01-252026-07-19
Mix3190d
- Insider15(48%)
- SEC Filings8(26%)
- Other6(19%)
- Earnings2(6%)
Latest news
25 items- INSIDERChief People Officer Lo Francis exercised 105,762 shares at a strike of $8.91 and sold $2,389,164 worth of shares (105,762 units at $22.59) as part of a pre-agreed trading plan (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2026 after market close on Wednesday, July 29, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hou
- INSIDERChief Scientific Officer Robins Harlan S sold $8,501,149 worth of shares (386,240 units at $22.01) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 1,019,658 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief People Officer Lo Francis exercised 75,621 shares at a strike of $8.75 and sold $2,157,683 worth of shares (95,842 units at $22.51) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 230,713 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $10,714 worth of shares (487 units at $22.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.12% to 406,288 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Ofc Imm Med Benzeno Sharon exercised 114,329 shares at a strike of $7.75 and sold $3,503,510 worth of shares (165,802 units at $21.13) as part of a pre-agreed trading plan, decreasing direct ownership by 19% to 221,278 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $102,500 worth of shares (5,000 units at $20.50) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 406,775 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERDirector Griffin Michelle Renee exercised 52,084 shares at a strike of $7.80 and sold $1,051,055 worth of shares (52,084 units at $20.18) as part of a pre-agreed trading plan (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECSEC Form 144 filed by Adaptive Biotechnologies Corporation144 - Adaptive Biotechnologies Corp (0001478320) (Subject)
- SECAdaptive Biotechnologies Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
- INSIDERChief Scientific Officer Robins Harlan S sold $1,847,942 worth of shares (106,160 units at $17.41) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 1,405,898 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAdaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes OfferingProceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of common stock to reduce potential dilutionRemaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes due 2031 (the "notes") in a private offering to persons reasonably believed to be qualified
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $95,000 worth of shares (5,000 units at $19.00) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 411,775 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECSEC Form 8-K filed by Adaptive Biotechnologies Corporation8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
- PRAdaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine BusinessesSEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company focused on translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capital needs, and value creation opportunities outside of Adaptive, and expects to identify its preferred path to separation by year-end 2026. Since establishing MRD and Immune Medicine as separate ope
- PRAdaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes OfferingProceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibilityAdditional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to $25 million of common stock to reduce potential dilutionRemaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD business SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a private offering to
- SECAdaptive Biotechnologies Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
- INSIDERChief People Officer Lo Francis exercised 19,521 shares at a strike of $8.85 and sold $695,070 worth of shares (39,741 units at $17.49) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 250,934 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- INSIDERChief Commercial Officer, MRD Bobulsky Susan sold $198,000 worth of shares (11,000 units at $18.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 416,775 units (SEC Form 4)4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- PRAt ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and ResearchSEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in 33 presentations, including one plenary session and 14 oral presentations, across the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 3 in Chicago, and the European Hematology Association (EHA) Congress, taking place June 11-14 in Stockholm. Data at ASCO a
- PRAdaptive Biotechnologies to Participate in Upcoming Investor ConferencesSEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Craig-Hallum 23rd Annual Institutional Investor Conference – Minneapolis, MNHosting 1x1 meetings on Thursday, May 28thWilliam Blair 46th Annual Growth Stock Conference – Chicago, ILPresentation on Wednesday, June 3rd at 3:20 p.m. Central Time Interested parties may access a live and archived webcast of the presentation from the William Blair Growth Stock Conf
- INSIDERChief Financial Officer Piskel Kyle sold $40,620 worth of shares (3,115 units at $13.04), decreasing direct ownership by 1% to 256,725 units (SEC Form 4) to satisfy tax liability4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Adaptive Biotechnologies CorporationSCHEDULE 13G/A - Adaptive Biotechnologies Corp (0001478320) (Subject)
- SECSEC Form 10-Q filed by Adaptive Biotechnologies Corporation10-Q - Adaptive Biotechnologies Corp (0001478320) (Filer)
- SECAdaptive Biotechnologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Adaptive Biotechnologies Corp (0001478320) (Filer)
ADPT FAQ
7 questionsWhat does Adaptive Biotechnologies Corporation do?
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and...Where does ADPT stock trade?
Adaptive Biotechnologies Corporation (ADPT) is listed on NASDAQ.What sector and industry is ADPT in?
Adaptive Biotechnologies Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Adaptive Biotechnologies Corporation go public?
Adaptive Biotechnologies Corporation (ADPT) completed its IPO in 2019.What are analysts saying about ADPT?
Adaptive Biotechnologies Corporation has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $2100.00 price target on 2025-12-02. Recent price targets range from $800.00 to $2100.00.What companies are similar to ADPT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ADPT side-by-side with any of them on Quantisnow.How can I track ADPT on Quantisnow?
Quantisnow aggregates Adaptive Biotechnologies Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADPT to receive live email and push alerts on every new disclosure.